NEW YORK (360Dx) – Paris, France-based Magnisense said Wednesday that it has raised €5 million ($5.7 million) in a new funding round.

Meusinvest, a Leige, Belgium-based investment fund, and three new private shareholders participated in the round alongside existing shareholders, including Provestis, Concorde Capital, and Minv.

Magnisense said that the funding will help boost the commercial presence of its test already on the market in Europe and support the development and launch of new tests based on its Miatek magnetic nanomaterial cardiac biomarker technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.